Literature DB >> 1333909

Assessment of chemoembolization therapy for primary liver cancer using a stabilized adriamycin-lipiodol suspension.

Y Horiguchi1, M Itoh, H Takagawa, H Imai, A Kamei, B Sekoguchi, Y Nagamura.   

Abstract

We formulated a new lipiodol-Adriamycin suspension (ADM/lipiodol, 50 mg/10 ml) that remained stable for 48 h (half-life, 25 +/- 3 days). In five cases of hepatocellular carcinoma (HCC) resected after intra-arterial infusion of this agent, the ADM concentration in the tumor was quite high and the tumor necrosis rate was more than 80% on histological examination. Over a 5-year period, 180 patients with unresectable HCC underwent transcatheter arterial embolization therapy (TAE) in the presence or absence of this agent. The regimens consisted of suspension injection alone (A, n = 54), suspension injection + TAE using gelatin sponge (B, n = 29), TAE followed by suspension injection (C, n = 34), and TAE alone (D, n = 63). The estimated 1-year survival values determined for patients treated with these regimens were 70%, 73%, 43%, and 39% respectively, and the corresponding 3-year survival values were 27%, 31%, 15%, and 10%. The survival achieved using suspension injection was thus superior to that obtained using conventional TAE, and combined therapy with suspension injection followed by TAE seemed to enhance survival, although there were some biases in tumor size and in the stage of tumor progression. For patients with tumors measuring 5 cm or more in diameter, the survival obtained using regimen A was lower than that achieved using regimen D, but the combination of TAE and suspension injection improved the 1-year survival value obtained using regimen D from 34% to 52%. For patients with tumors measuring less than 5 cm in diameter, the survival achieved using regimen A was markedly better than that obtained using regimen D, although no difference was found between the survival value achieved using regimen A and that obtained using regimens B and C. On the basis of these results, our newly formulated ADM-lipiodol suspension was surmised to be effective by itself against relatively small HCC tumors, whereas it enhanced the efficacy of conventional TAE in large lesions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1333909     DOI: 10.1007/bf00687107

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Combined peripheral and central chemoembolization of liver tumors. Experience with lipiodol-doxorubicin and gelatin sponge (L-TAE).

Authors:  Y Shimamura; P Gunvèn; Y Takenaka; H Shimizu; Y Shima; H Akimoto; K Arima; A Takahashi; T Kitaya; T Matsuyama
Journal:  Cancer       Date:  1988-01-15       Impact factor: 6.860

2.  A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge.

Authors:  Y Sasaki; S Imaoka; H Kasugai; M Fujita; S Kawamoto; S Ishiguro; J Kojima; O Ishikawa; H Ohigashi; H Furukawa
Journal:  Cancer       Date:  1987-09-15       Impact factor: 6.860

3.  Hepatic artery embolization in 120 patients with unresectable hepatoma.

Authors:  R Yamada; M Sato; M Kawabata; H Nakatsuka; K Nakamura; S Takashima
Journal:  Radiology       Date:  1983-08       Impact factor: 11.105

4.  Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents.

Authors:  K Takayasu; Y Shima; Y Muramatsu; N Moriyama; T Yamada; M Makuuchi; H Hasegawa; S Hirohashi
Journal:  Radiology       Date:  1987-05       Impact factor: 11.105

5.  Transcatheter arterial embolization for hepatocellular carcinoma. Benefits and limitations for unresectable cases with liver cirrhosis evaluated by comparison with other conservative treatments.

Authors:  Y Sato; K Fujiwara; I Ogata; Y Ohta; S Hayashi; Y Oka; S Furui; H Oka
Journal:  Cancer       Date:  1985-06-15       Impact factor: 6.860

6.  Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents.

Authors:  H Ohishi; H Uchida; H Yoshimura; S Ohue; J Ueda; M Katsuragi; N Matsuo; Y Hosogi
Journal:  Radiology       Date:  1985-01       Impact factor: 11.105

7.  [Basic study of anti-cancer agents suspended in lipiodol].

Authors:  H Taniguchi; T Yamaguchi; T Takahashi
Journal:  Gan To Kagaku Ryoho       Date:  1986-02

8.  Transcatheter oily chemoembolization of hepatocellular carcinoma.

Authors:  H Nakamura; T Hashimoto; H Oi; S Sawada
Journal:  Radiology       Date:  1989-03       Impact factor: 11.105

9.  Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium.

Authors:  T Konno; H Maeda; K Iwai; S Maki; S Tashiro; M Uchida; Y Miyauchi
Journal:  Cancer       Date:  1984-12-01       Impact factor: 6.860

  9 in total
  5 in total

1.  Techniques of interventional tumor therapy.

Authors:  Andreas H Mahnken; Philipp Bruners; Rolf W Günther
Journal:  Dtsch Arztebl Int       Date:  2008-09-19       Impact factor: 5.594

2.  Treatment of choice for unresectable small liver cancer: percutaneous ethanol injection therapy or transarterial chemoembolization therapy.

Authors:  Y Horiguchi; B Sekoguchi; H Imai; T Suzuki; H Kubo; H Itoh; M Itoh
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Cryotherapy for liver metastases.

Authors:  Malgorzata M Bala; Robert P Riemsma; Robert Wolff; Michal Pedziwiatr; Jerzy W Mitus; Dawid Storman; Mateusz J Swierz; Jos Kleijnen
Journal:  Cochrane Database Syst Rev       Date:  2019-07-10

4.  Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.

Authors:  S Kishimoto; K Miyazawa; Y Terakawa; H Ashikari; A Ohtani; S Fukushima; Y Takeuchi
Journal:  Jpn J Cancer Res       Date:  2000-12

Review 5.  [Update on chemoinfusion and chemoembolization treatments].

Authors:  A Lubienski; M Simon; K Lubienski; J Gellissen; R-T Hoffmann; T F Jakobs; T Helmberger
Journal:  Radiologe       Date:  2007-12       Impact factor: 0.803

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.